GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (STU:RFS) » Definitions » Shiller PE Ratio

Resverlogix (STU:RFS) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Resverlogix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix Shiller PE Ratio Historical Data

The historical data trend for Resverlogix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Shiller PE Ratio Chart

Resverlogix Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Resverlogix's Shiller PE Ratio

For the Biotechnology subindustry, Resverlogix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Resverlogix's Shiller PE Ratio falls into.


;
;

Resverlogix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Resverlogix's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Resverlogix's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0/127.3637*127.3637
=0.000

Current CPI (Dec. 2024) = 127.3637.

Resverlogix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201501 -0.017 98.209 -0.022
201504 -0.222 99.710 -0.284
201507 0.027 100.579 0.034
201510 -0.036 100.500 -0.046
201601 -0.074 100.184 -0.094
201604 -0.088 101.370 -0.111
201607 -0.054 101.844 -0.068
201610 -0.127 102.002 -0.159
201701 -0.113 102.318 -0.141
201704 -0.103 103.029 -0.127
201707 -0.121 103.029 -0.150
201710 -0.085 103.424 -0.105
201801 -0.123 104.056 -0.151
201804 -0.016 105.320 -0.019
201807 -0.240 106.110 -0.288
201810 -0.183 105.952 -0.220
201901 -0.061 105.557 -0.074
201904 -0.285 107.453 -0.338
201907 0.018 108.243 0.021
201910 0.416 107.927 0.491
202001 0.018 108.085 0.021
202004 0.037 107.216 0.044
202007 -0.026 108.401 -0.031
202010 -0.017 108.638 -0.020
202103 0.000 110.298 0.000
202106 -0.008 111.720 -0.009
202109 -0.017 112.905 -0.019
202112 -0.062 113.774 -0.069
202203 -0.009 117.646 -0.010
202206 -0.002 120.806 -0.002
202209 -0.010 120.648 -0.011
202212 0.009 120.964 0.009
202303 -0.019 122.702 -0.020
202306 -0.009 124.203 -0.009
202309 -0.019 125.230 -0.019
202312 -0.009 125.072 -0.009
202403 0.003 126.258 0.003
202406 -0.019 127.522 -0.019
202409 -0.018 127.285 -0.018
202412 0.000 127.364 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix  (STU:RFS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Resverlogix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Resverlogix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines

No Headlines